10:53 AM EST, 11/04/2024 (MT Newswires) -- AstraZeneca ( AZN ) said its experimental obesity pill was well-tolerated by patients with type-2 diabetes, Bloomberg reported Monday, citing comments made by a company executive at the ObesityWeek conference in San Antonio, Texas.

Over four weeks in an early study, the oral GLP-1 resulted in patients losing an average of 5.8% of their body weight, said Sharon Barr, executive vice president of biopharmaceuticals R&D, according to the report.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 71.45, Change: +0.03, Percent Change: +0.04